Clinical Trials Logo

Heart Failure clinical trials

View clinical trials related to Heart Failure.

Filter by:

NCT ID: NCT05072054 Recruiting - Clinical trials for Heart Failure With Reduced Ejection Fraction

Comparison of Effects of Atorvastatin Versus Rosuvastatin on Cardiac Function in Heart Failure Patients

ASTRO-CHF
Start date: October 16, 2019
Phase: Phase 4
Study type: Interventional

Statins have a protective effect in patients with established heart failure because of their lipid-lowering and pleiotropic effects. There is no randomized controlled trial comparing lipophilic versus hydrophilic statins in these patients (head to head comparison). The best evidence so far is from a meta-analysis in which the authors did an adjusted indirect comparison between lipophilic statins and rosuvastatin and found that lipophilic statins were associated with significantly lower incidence of all-cause mortality, cardiovascular mortality, and hospitalization for worsening heart failure compared to rosuvastatin (hydrophilic statin) among patients with heart failure. So, the investigators plan to conduct a randomized controlled trial comparing the effects of atorvastatin and rosuvastatin on cardiac function in patients with heart failure with reduced ejection fraction.

NCT ID: NCT05064709 Recruiting - Heart Failure Clinical Trials

Assessment of CCM in HF With Higher Ejection Fraction

AIM HIGHer
Start date: February 3, 2022
Phase: N/A
Study type: Interventional

The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤60%.

NCT ID: NCT05063955 Recruiting - Heart Failure Clinical Trials

Mechanism of Sarcopenia in Heart Failure

MUSCLE-CHF
Start date: December 2, 2020
Phase:
Study type: Observational [Patient Registry]

The aim of the study is to provide information on the interaction between socioeconomic factors, daily physical activity, nutrition and lifestyle on loss of muscle mass and muscle function in patients with heart failure.

NCT ID: NCT05059769 Recruiting - Clinical trials for Heart Failure With Preserved Ejection Fraction

Relationship Between Ambulatory Arterial Stiffness Index and Left Ventricular Diastolic Function in Patients With HFpEF

Start date: October 10, 2020
Phase:
Study type: Observational [Patient Registry]

Heart failure with preserved ejection fraction (HFpEF) was considered as a heterogeneous disease with multi-organ and multi-system design, which is related to various complications, such as hypertension, obesity and arteriosclerosis. Ambulatory arterial stiffness index (AASI) is associated with arteriosclerosis and hypertension. There is no report on whether AASI is associated with left ventricular diastolic dysfunction in patients with HFpEF.

NCT ID: NCT05057806 Recruiting - Type2 Diabetes Clinical Trials

SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan

Start date: January 13, 2021
Phase: Early Phase 1
Study type: Interventional

The study team will examine the effects of SGLT2i (and SGLT2i-induced increases in plasma ketone concentrations) on skeletal muscle and cardiac ketone uptake, skeletal muscle bioenergetics, cardiopulmonary exercise capacity, and patient-reported functional outcomes.

NCT ID: NCT05056649 Recruiting - Heart Failure Clinical Trials

The Role of the GP in the Management of Ambulatory Heart Failure

GPsHF
Start date: October 1, 2022
Phase:
Study type: Observational

To describe the causes mentioned by general practitioners, explaining the under-treatment of the three main treatments for heart failure with impaired ejection fraction (ARS blockers of the type ACEinhibitor/ARA2/ARNi, ß- and/or anti-aldosterone).

NCT ID: NCT05056129 Recruiting - Heart Failure Clinical Trials

Sensor-controlled Digital Game for Heart Failure Self-management: A Clinical Trial

SCDG
Start date: November 1, 2022
Phase: N/A
Study type: Interventional

This study evaluates a sensor-controlled digital game (SCDG) to motivate self-management behaviors of weight monitoring and physical activity in adults with heart failure (HF). Half of the participants will receive the SCDG app and weight monitoring and physical activity sensors and the other half will receive only the weight monitoring and physical activity sensors.

NCT ID: NCT05055180 Recruiting - Clinical trials for Heart Failure With Preserved Ejection Fraction

Right Ventricular Function and Pulmonary Hypertension in HFpEF

HFpEF-PHT
Start date: October 1, 2018
Phase:
Study type: Observational

In patients with heart failure and preserved ejection fraction (HFpEF) right ventricular (RV) systolic and diastolic dysfunction are prognostically and functionally relevant factors but have mechanistically been neglected so far. In the present study alterations of intrinsic RV (systolic and diastolic) function, as assessed by invasive pressure volume loops, are examined in relation to tissue alterations on myocardial level and to the degree of RV afterload (pulmonary hypertension). Study aim is to gain insights into mechanisms contributing to the development of RV dysfunction and potentially identify new therapeutic targets.

NCT ID: NCT05053568 Recruiting - Heart Failure Clinical Trials

Image Supported Lead Placement in CRT

ADVISE
Start date: February 8, 2021
Phase: N/A
Study type: Interventional

Cardiac resynchronization therapy (CRT) is an established pacemaker therapy for patients with symptomatic chronic heart failure, but is hampered by a non-response rate of 30-40%. Optimising left ventricular (LV) lead placement is the cornerstone of improving treatment. The optimal location for the lead is remote from scar but within segments demonstrating late electromechanical activation. The present study aims to investigate the efficacy and clinical effect of the use of real-time guided lead placement using cardiac MRI and fluoroscopy in a blinded, multicenter, randomized controlled trial.

NCT ID: NCT05053256 Recruiting - Clinical trials for Heart Failure With Preserved Ejection Fraction

The Relationship Between Heart Function and Metabolism in HFpEF Patients

Start date: October 1, 2021
Phase:
Study type: Observational

HFpEF has gradually become the most common form of heart failure. Studies have found that metabolic abnormalities and chronic inflammation ultimately lead to HFpEF by promoting heart remodeling. However, there are few relevant studies and the mechanism is still unclear.